IMMUNOTOXIN-DEPLETION OF HIV-1+T CELLS
IMMUNOTOXIN-DEPLETION OF HIV-1+T CELLS
批准号:
6511507
负责人:
ELLEN S VITETTA
金额:
$31.29万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-07-01 至 2004-06-30
关键词:
AIDS therapy T lymphocyte antiAIDS agent cell death cell population study cytotoxic T lymphocyte cytotoxicity drug screening /evaluation flow cytometry helper T lymphocyte human immunodeficiency virus 1 human subject human therapy evaluation immunoconjugates immunologic memory immunotoxicity indicator dilution test patient oriented research polymerase chain reaction suppressor T lymphocyte
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: We have previously demonstrated that an immunotoxin (IT) directed
against CD45RO and containing chemically deglycosylated ricin toxin A chain
(dgA), kills CD4-postive human T-cells which are both latently and actively
infected with HIV-1 in vitro. We now propose to determine whether this IT can
kill infected T-cells from HIV positive individuals and, in particular, latent
cells from individuals receiving HAART. This study will involve perfecting a
highly sensitive limiting dilution assay to determine the frequency of
replication-competent cells. Experiments will include both in vitro- and in
vivo-infected CD4-postive T cells infected with drug-resistant and
drug-sensitive isolates of HIV-1. If the IT effectively kills the target cells,
we will then determine what effect it has on immune memory in the CD4-positive
and CD8-positive T-cell populations. This will be accomplished by treating
peripheral blood cells from both HIV-negative and HIV-positive individuals with
the IT and then activating cells with mitogens, superantigens, and antigens.
Flow cytometry will then be used to evaluate intracellular cytokines in
sub-populations of naive and memory CD4-postive and CD8-postive T-cells to
determine whether T cell memory is compromised. This is a preclinical study to
evaluate a new therapeutic modality. Our results should determine the
feasibility of a future clinical trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel vaccine to prevent HCV infection and hence liver cancer
-
批准号:7943947
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2009
-
负责人:ELLEN S VITETTA
-
依托单位:
A novel vaccine to prevent HCV infection and hence liver cancer
-
批准号:7852639
-
项目类别:
-
资助金额:$68.37万
-
财政年份:2009
-
负责人:ELLEN S VITETTA
-
依托单位:
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
-
批准号:7475286
-
项目类别:
-
资助金额:$32.17万
-
财政年份:2007
-
负责人:ELLEN S VITETTA
-
依托单位:
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
-
批准号:7213715
-
项目类别:
-
资助金额:$30.77万
-
财政年份:2007
-
负责人:ELLEN S VITETTA
-
依托单位:
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
-
批准号:7623849
-
项目类别:
-
资助金额:$31.19万
-
财政年份:2007
-
负责人:ELLEN S VITETTA
-
依托单位:
Development of a lyophilized intradermal/intranasal ricin vaccine
-
批准号:7133314
-
项目类别:
-
资助金额:$76.45万
-
财政年份:2006
-
负责人:ELLEN S VITETTA
-
依托单位:
Development of a lyophilized intradermal/intranasal ricin vaccine
-
批准号:7255730
-
项目类别:
-
资助金额:$58.83万
-
财政年份:2006
-
负责人:ELLEN S VITETTA
-
依托单位:
Development of a lyophilized intradermal/intranasal ricin vaccine
-
批准号:7643996
-
项目类别:
-
资助金额:$54.03万
-
财政年份:2006
-
负责人:ELLEN S VITETTA
-
依托单位:
Development of a lyophilized intradermal/intranasal ricin vaccine
-
批准号:7446146
-
项目类别:
-
资助金额:$61.57万
-
财政年份:2006
-
负责人:ELLEN S VITETTA
-
依托单位:
Development of a lyophilized intradermal/intranasal ricin vaccine
-
批准号:7871434
-
项目类别:
-
资助金额:$73.51万
-
财政年份:2006
-
负责人:ELLEN S VITETTA
-
依托单位:
IMMUNOTOXIN-DEPLETION OF HIV-1+ T CELLS
-
批准号:7165197
-
项目类别:
-
资助金额:$9.42万
-
财政年份:2005
-
负责人:ELLEN S VITETTA
-
依托单位:
The reversal of multidrug resistance by an anti-CD19 ab.
-
批准号:6892860
-
项目类别:
-
资助金额:$24.57万
-
财政年份:2004
-
负责人:ELLEN S VITETTA
-
依托单位:
IMMUNOTOXIN-DEPLETION OF HIV-1+ T CELLS
-
批准号:6970631
-
项目类别:
-
资助金额:$5.27万
-
财政年份:2004
-
负责人:ELLEN S VITETTA
-
依托单位:
The reversal of multidrug resistance by an anti-CD19 ab.
-
批准号:6703394
-
项目类别:
-
资助金额:$24.57万
-
财政年份:2004
-
负责人:ELLEN S VITETTA
-
依托单位:
The reversal of multidrug resistance by an anti-CD19 ab.
-
批准号:7060397
-
项目类别:
-
资助金额:$23.99万
-
财政年份:2004
-
负责人:ELLEN S VITETTA
-
依托单位:
A Novel Recombinant Protein Vaccine Against Ricin Toxin
-
批准号:6796651
-
项目类别:
-
资助金额:$70.18万
-
财政年份:2003
-
负责人:ELLEN S VITETTA
-
依托单位:
A Novel Recombinant Protein Vaccine Against Ricin Toxin
-
批准号:6862775
-
项目类别:
-
资助金额:$67.88万
-
财政年份:2003
-
负责人:ELLEN S VITETTA
-
依托单位:
A Novel Recombinant Protein Vaccine Against Ricin Toxin
-
批准号:7019153
-
项目类别:
-
资助金额:$60.5万
-
财政年份:2003
-
负责人:ELLEN S VITETTA
-
依托单位:
A Novel Recombinant Protein Vaccine Against Ricin Toxin
-
批准号:6681436
-
项目类别:
-
资助金额:$63.59万
-
财政年份:2003
-
负责人:ELLEN S VITETTA
-
依托单位:
IMMUNOTOXIN-DEPLETION OF HIV-1+T CELLS
-
批准号:6632422
-
项目类别:
-
资助金额:$31.29万
-
财政年份:2001
-
负责人:ELLEN S VITETTA
-
依托单位:
海外基金